OncoMatch/Clinical Trials/NCT05010031
A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change
Is NCT05010031 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for metastatic cancer.
This study will test whether reduced-dose radiotherapy is an effective treatment for metastatic tumors with an ATM mutation. The researchers want to find the lowest dose of radiation that would still be effective to treat these tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Biomarker criteria
Required: ATM pathogenic mutation
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: radiation therapy
Exception: only if previous radiotherapy to the intended treatment site precludes developing a treatment plan that respects normal tissue tolerances
Previous radiotherapy to the intended treatment site that precludes developing a treatment plan that respects normal tissue tolerances.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (All protocol activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (All protocol activities) · Montvale, New Jersey
- Memorial Sloan Kettering Commack (All protocol activities) · Commack, New York
- Memorial Sloan Kettering Westchester (All Protocol Activities) · Harrison, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify